Ethos Technologies Inc (LIFE)
NASDAQFinancialsInsurance - BrokersSnapshot 2026-09-04
NASDAQFinancialsInsurance - BrokersSnapshot 2026-09-04
Research Workspace
Put LIFE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Improve adjusted EBITDA to $103M-$107M for 2026: FY26 EBITDA guidance $119M-$123M vs ~$105M target.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 3% a day.
View RiskLIFE's revenue growth must continue to justify its current valuation. Revenue grew 113% year over year, and the latest quarter beat expectations. It trades at 29× P/E versus a peer median of 12×, indicating a significant premium. The price reflects less growth than forecast, suggesting modest expectations. A specific risk is the need to achieve adjusted EBITDA guidance of $103 million to $107 million for 2026, as the primary pillar is under pressure. Peer multiples imply a price about 73% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-09-04. LIFE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering LIFE (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for LIFE in the last 4 months.
Continue this research
Compare LIFE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LIFE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Insurance Brokers — fair value, gap to price, and forward P/E.
Compare the value case
Put LIFE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Achieve revenue guidance for 2026
Revenue growth is strong, but margin compression is concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $39.85
The last 12 months of price, then the range of analyst 12-month targets from today’s $39.85.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Threatens: Address earnings miss
Stock drop indicates potential loss of investor confidence.